Recombinant RSV G proteins and their use
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorSurender Khurana
Life of this patent
Estimating the term…
Abstract
Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.
Claims28
A recombinant respiratory syncytial virus (RSV) G ectodomain comprising:
- a deletion of RSV G residues 1-66 and 172-186 with residues 171 and 187 directly linked by a peptide bond, or indirectly linked by a peptide linker;
- wherein the recombinant RSV G ectodomain does not include a transmembrane domain or cytosolic tail;
- and
- wherein the amino acid positions correspond to SEQ ID NO:
- 1.
A recombinant respiratory syncytial virus (RSV) G ectodomain comprising:
- a deletion of RSV G residues 172-186 with residues 171 and 187 indirectly linked by a peptide linker, linked to an N-terminal RSV G transmembrane domain and cytosolic tail;
- wherein the recombinant RSV G ectodomain linked to the N-terminal RSV G transmembrane domain and cytosolic tail comprises an amino acid sequence at least 90% identical to SEQ ID NO:
- 6 or SEQ ID NO:
- 15,
- wherein the amino acid positions correspond to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.